ATLASAcrivon Therapeutics (ACRV) earnings date: Nov 12, 2026
Acrivon Therapeutics (ACRV) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 12, 2026. Analysts expect EPS of -$0.45.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on ACRV
| Last price | $1.62 (-2.4%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.0% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Acrivon Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Acrivon Therapeutics reports on Nov 12, 2026. One email the day before, with ATLAS’s read on Acrivon Therapeutics. You can switch it off at any time.
Alert me before ACRV reportsFree to start. Creating an account takes under a minute.
Notify me when Acrivon Therapeutics reports
Track ACRV free Add Acrivon Therapeutics to a free ATLAS watchlist and see its next report date in one place.
ACRV earnings at a glance
| Next report (confirmed) | Thu, Nov 12, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.45 |
| Last report | Aug 12, 2026 · Beat |
| Beat rate (last 4 reports) | 3 of 4 (75%) |
| Average EPS surprise | +23.3% |
| Average move around a report | ±2.9% (last 4) |
| Sector | Healthcare · Biotechnology |
Acrivon Therapeutics earnings history: last 4 reports
Acrivon Therapeutics last reported on Aug 12, 2026: EPS of -$0.43 against an estimate of -$0.50 (+14.0% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 12, 2026 | -$0.50 | -$0.43 | +14.0% | Beat | +6.9% |
| May 13, 2026 | $0.03 | $0.05 | +66.7% | Beat | +1.6% |
| Mar 19, 2026 | -$0.46 | -$0.49 | -6.5% | Miss | +1.2% |
| Nov 13, 2025 | -$0.58 | -$0.47 | +19.0% | Beat | -1.8% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for ACRV
See the fair value, the probability range and the earnings history of Acrivon Therapeutics on its ATLAS page.
Acrivon Therapeutics (ACRV) stock analysisPlans from €3.99 a month.
Acrivon Therapeutics earnings: frequently asked questions
When does Acrivon Therapeutics (ACRV) report earnings?
Acrivon Therapeutics is scheduled to report on Thursday, November 12, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for ACRV?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.45 per share (USD). Estimates can change before the report.
How often does ACRV beat earnings estimates?
Of its last 4 reports with a recorded result, Acrivon Therapeutics beat the EPS estimate 3 times; the average surprise was +23.3%. Past results do not predict the next one.
How much does ACRV move around earnings?
Over its last 4 reports the stock moved an average of 2.9% (absolute, from the close before the report day to the close after it), and finished higher 3 of 4 times.
Did Acrivon Therapeutics beat earnings estimates last quarter?
Acrivon Therapeutics last reported on Aug 12, 2026: EPS of -$0.43 against an estimate of -$0.50 (+14.0% surprise), a beat.
How much does ACRV usually move in a day?
On a normal trading day the ATLAS model puts ACRV’s one-day range at about ±4.0%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 12, 2026
Educational information, not investment advice. Disclaimer